What Histofy does

Histofy is a UK-based software company that develops transparent artificial intelligence solutions for computational pathology, with a focus on tissue-based diagnostics and prognostics. The company is a spinout from the Tissue Image Analytics (TIA) Centre at the University of Warwick, founded by Professor Nasir Rajpoot (CEO and CSO), Professor David Snead (CMO), and Dr Simon Graham (CTO), whose combined research output exceeds 250 peer-reviewed publications spanning more than 20 years. Its product portfolio comprises five core AI tools: MitPro® for mitosis counting and hotspot identification across H&E whole-slide images; CoBi for colon biopsy screening that filters normal slides and triages abnormal cases; GI-Miner for deep gastrointestinal tissue profiling using the proprietary Measurable Attributes for Pathology (MAPs) interpretability framework; Beagle, an agentic AI companion for toxicologic pathology studies; and the Helix platform for large-scale annotation of digital pathology images. Underlying capabilities include computer vision across 10+ cancer types, multi-modal predictive analytics combining pathology with genomics/transcriptomics/epigenetics, and agentic AI workflows for drug development.

Histofy serves four primary customer segments: clinical hospital pathology laboratories (notably NHS trusts), academic medical centers and research hospitals, pharmaceutical companies for drug development and toxicologic studies, and laboratory service providers. Distribution is multi-channel: direct enterprise sales to NHS and pharma, channel partnerships (Leica Biosystems global reseller for MitPro via the Aperio AI Store; Source BioScience for UK commercial labs), and marketplace listings across the dominant digital pathology platforms (Paige AppLab, Indica Labs HALO AP, Sectra Amplifier). Geographic footprint spans the United Kingdom, Spain, Norway, South Korea, and broader Europe, with validation studies at 10 NHS sites and data partnerships with MD Anderson Cancer Center España, West Midlands Secure Data Environment, Cancer Research Horizons (S:CORT dataset), and Haukeland University Hospital.

The business model rests on AI software licensing (including royalties through channel partners), professional services for validation studies and clinical workflow integration, and grant-funded research collaborations. Products are designated for research use only while CE-IVDR regulatory approval is pursued, positioning the company for clinical commercialization once regulatory milestones clear. The company has achieved ISO/IEC 27001 and ISO 13485 certification from BSI and is a member of NVIDIA Inception and Google Cloud partner programs, with headquarters at the University of Warwick Science Park in Coventry, UK.

Name

Histofy

Legal name

Histofy Ltd

Website

https://histofy.ai

Company type

Private

Founded year

2023

Operating status

Operating

Headcount range

1–10 employees

Short description

Histofy is a UK-based AI software company developing transparent computational pathology tools (MitPro, CoBi, GI-Miner, Beagle, Helix) for NHS trusts, academic medical centers, pharmaceutical companies, and laboratory service providers across Europe, Asia, and Norway.

Ownership category

akta.pro rank

Product category

Digital Pathology AI Software

NAICS

Software Publishers (5132), Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Laboratory Analytical Instruments (3826)

akta.pro primary industry

Digital & AI-Enabled Diagnostics (algorithmic interpretation, decision support tied to assays) (HLAAALAO)

akta.pro secondary industries

Anatomic Pathology & Histology/Cytology IVD (Tissue Diagnostics) (HLAHAAAE), Molecular Pathology & Tissue Biomarkers (IHC/ISH, digital pathology-linked markers) (HLAAAMAI)

Keywords

• Computational pathology AI
• Digital pathology software
• AI mitosis profiling
• Colon biopsy screening AI
• Whole-slide image analytics

Headquarters

HQ city

Birmingham

HQ country

United Kingdom

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Software

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

1. AI Software Licensing: Histofy licenses its AI pathology software tools (MitPro, GI-Miner, Beagle, COBI) to healthcare providers, pharmaceutical companies, and research institutions. Distribution occurs through direct enterprise agreements, channel reseller partnerships (Leica Biosystems), and marketplace platforms (Paige AppLab, Sectra Amplifier, Indica Labs HALO AP). Revenue is generated through software licenses, with tools typically designated for research use while pursuing CE-IVDR regulatory approval for clinical use.
2. Professional Services & Validation Studies: The company conducts validation studies with NHS sites and academic partners, providing services for algorithm integration into clinical workflows and performing large-scale validation using biopsy samples across multiple sites. The NIHR-funded consortium valued the overall project at £2.6M over three years, with Histofy securing over £500K as the commercial partner.

Pricing tiers

Go-to-market motion3 records

Distribution channels6 records

Marketing channels4 records

Core offering

Histofy develops transparent AI software for computational pathology that analyzes H&E-stained whole-slide images to automate tasks such as mitosis counting, colon biopsy screening, gastrointestinal tissue profiling, and toxicologic pathology study support. Its products (MitPro, CoBi, GI-Miner, Beagle) and the Helix annotation platform are licensed to hospital pathology labs, pharmaceutical companies, and academic research institutions via direct sales and channel partnerships with major digital pathology platform providers.

Product overview

Histofy is a multi-product AI pathology platform comprising four core products: MitPro® for automated mitosis counting and cancer grading, CoBi for AI-powered colon biopsy screening, GI-Miner for deep GI tissue profiling with Measurable Attributes for Pathology (MAPs), and Beagle as an agentic AI companion for toxicologic pathology. Additionally, the proprietary Helix platform provides large-scale annotation capabilities. All products integrate with established digital pathology platforms including Aperio HALO AP, HALO AP®, Sectra, and Paige AppLab™.

Differentiator

Problem solved

Functional benefit

Brands

• MitPro®: AI-driven solution for precise mitosis quantification and profiling across H&E whole-slide images, used for cancer grading applications.
• GI-Miner
• Beagle
• Helix

Products and services

• MitPro AI-driven solution for precise mitosis quantification and profiling across H&E whole-slide images. Detects mitotic figures across entire slides, identifies the three highest-scoring hotspots, and supports pathologist verification. Validated for breast, lung, melanoma, soft tissue sarcoma, leiomyoma, neuroendocrine tumors, glioblastoma, meningioma, thyroid, and retinoblastoma. Designated for research use while pursuing CE-IVDR approval.
• CoBi (Colon Biopsy Screening) AI-powered colon biopsy screening tool that filters normal slides that do not require pathologist intervention and provides triaging and decision support for flagged abnormal slides. Validated across 10 NHS sites. Targets NHS pathology labs facing staff shortages.
• GI-Miner Suite of tools for quantification of deep cellular and multi-cellular pathologist-friendly interpretable numerical features (Measurable Attributes for Pathology / MAPs) from gastrointestinal pathology images. Detects nuclei types, goblet cells, signet ring cells, 15+ tissue types, glands/lumen, and pigment-laden macrophages.
• Beagle Agentic AI companion for toxicologic pathology studies. Empowers toxicologic scientists to interrogate complex study data, integrate findings with internal/external sources, and accelerate study report drafting and decision-making.
• Helix Platform Proprietary platform for rich, clinically relevant annotation of digital pathology images at scale. Used to enhance over 500,000 whole-slide images with expert-validated histological features for NHS research and AI development.

Quantifiable outcome

• 97% of NHS pathology labs facing staff shortages, creating urgent demand for AI assistance
• +3 more outcomes

Named customers4 records

Segments4 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration4 records

AI capability9 records

Feature5 records

Partnerships

Eleven partnerships are on record, tiered core, major and minor.

• West Midlands Secure Data Environment (WMSDE)coreStrategic or Co-development Partner · 11 February 2026Contract (February 2026) for Histofy to provide Helix platform access for advanced annotation and AI-driven enrichment of whole-slide images. Project enhances over 500,000 images already hosted within SDE, making dataset significantly more valuable for researchers and AI developers.
• Leica BiosystemscoreChannel Partner/ Reseller/ Distributor · 6 September 2025Global reseller agreement (September 2025) for AI-powered pathology solutions. Leica Biosystems resells Histofy's MitPro via the Aperio AI Store and integrates with Aperio HALO AP platform. Partnership combines Histofy's AI technology with Leica's global reach and digital pathology expertise.
• Fundación MD Anderson Cancer Center EspañacoreStrategic or Co-development Partner · 4 June 2025Exclusive partnership (June 2025) providing Histofy time-limited exclusive access to one of Europe's most comprehensive collections of digitized pathology slides and clinical data. Partnership enables accelerated development and validation of AI algorithms for enhanced diagnostic accuracy and personalized treatment pathways.
• Source BioSciencecoreStrategic or Co-development Partner · 5 May 2025Strategic partnership (May 2025) with UK's largest histopathology service provider to integrate Histofy's AI technology into Source BioScience's state-of-the-art pathology laboratories. Initiative focuses on enhancing laboratory workflows and accelerating diagnostic services with view to scaling across full range of laboratory services.
• Cancer Research HorizonscoreStrategic or Co-development Partner · 8 April 2025Non-exclusive licensing of S:CORT multi-modal dataset (1,700+ colorectal cancer patients across 11 cohorts) enabling Histofy to develop AI models that stratify patients based on progressive disease likelihood and treatment response prediction for personalized colorectal cancer treatment.
• Haukeland University HospitalmajorStrategic or Co-development Partner · 14 October 2024Partnership (October 2024) with Norway's premier medical institution to develop AI tool for colon polyp classification. Histofy leads development using clinical data and expertise from HUH to classify polyps more efficiently, streamline workflows, and deliver faster, more consistent results.
• Indica LabscoreTechnology or Integration · 3 June 2024Integration (June 2024) of Histofy AI tools into HALO AP platform (CE-IVDR marked for EU/UK/Switzerland; FDA cleared HALO AP Dx in US). Partnership enables seamless integration of cutting-edge AI into pathologist workflows for enhanced diagnostic capabilities.
• PaigecoreTechnology or Integration · 14 February 2024Partnership (February 2024) to offer Histofy AI models via Paige AppLab marketplace. Products accessible from Paige Platform and FullFocus viewer, enabling pathologists to browse, trial, and purchase AI tools. Initial offerings include MitPro and COBi tools.
• CNAI and Korea UniversityminorStrategic or Co-development Partner · 20 March 2023Innovate UK and KAIT funded collaboration (March 2023) under UK-South Korea Collaborative R&D scheme to develop MitProfiler, a cloud-based AI solution for profiling mitotic figures. Histofy leads data collection and algorithm refinement; CNAI develops cloud architecture; Korea University researches domain-invariant detection methods.
• NIHR-funded ConsortiumcoreStrategic or Co-development Partner · 10 March 2023£2.6M NIHR-funded project (March 2023) with 10 NHS sites providing 10,000 biopsy samples for large-scale validation of colon biopsy screening AI. Histofy secured £500K+ as sole commercial partner responsible for productizing technology and integrating within hospital systems.
• TIA Centre, University of WarwickcoreStrategic or Co-development PartnerSpinout origin. Histofy originated from the Tissue Image Analytics (TIA) Centre at University of Warwick, which has produced over 250 publications spanning 20+ years of research. Continued collaboration on AI pathology innovation.

Scale indicators7 records

Recent moves7 records

Expansion highlights7 records

Direct peers

• Paige.AI: Directly competes with Histofy in AI-powered computational pathology and is also a distribution partner via Paige AppLab. Paige has FDA-authorised AI products (e.g., Paige Prostate) and offers a pathology viewer/marketplace that Histofy rides on, making it the closest comparable in business model and product.
• Ibex Medical Analytics: Direct competitor in AI-based cancer diagnostics for pathology, with clinically deployed products for breast and prostate cancer detection. Targets the same hospital laboratory customer segment as Histofy's MitPro and COBI.
• PathAI: Direct peer in AI pathology, with both diagnostic and pharma/biopharma offerings (including a CRO-like service). PathAI's AISight and IQ model offerings overlap directly with Histofy's MitPro and disease-stratification use cases.
• Owkin: AI-for-pathology and oncology company combining whole-slide imaging with multi-omics for patient stratification. Overlaps with Histofy's S:CORT-based stratification work and serves the same pharma R&D segment.
• Proscia: Digital pathology platform with AI applications including prostate and breast cancer detection. Competes for the same clinical laboratory software budget and offers an OEM-style platform similar to Histofy's HALO AP integration strategy.

Emerging players

• Aiosyn: Early-stage computational pathology company developing AI algorithms for pathology image analysis (e.g., nuclei detection, kidney pathology). Smaller and more focused than Histofy but competes in the same algorithmic pathology segment.
• Mindpeak: AI pathology company offering tools for breast cancer (Ki-67, HER2) and other tissue-based diagnostics. Comparable to Histofy's MitPro and GI-Miner in delivering pathologist-facing quantitative features.

Broad incumbents

• Lunit: Larger, publicly listed medical-AI company whose Lunit SCOPE platform provides AI biomarkers on H&E pathology images. Competes with Histofy in pathology AI but operates across broader medical imaging including radiology.

Others

• Indica Labs: Digital pathology platform vendor (HALO AP) that both distributes Histofy AI tools and offers its own AI applications. Relevant as a partner/incumbent defining the platform layer that AI pathology apps, including Histofy's, must integrate into.
• Leica Biosystems: Global digital pathology platform vendor (Aperio) that resells Histofy's MitPro via the Aperio AI Store. Functions as Histofy's primary global distribution channel rather than a direct AI competitor.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks5 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/histofy

Compliance3 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles9 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Histofy